Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of C

Indication
Urothelial Cancer

Other upcoming events for BMY

Phase 3 ReadoutPhase 3 Topline: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to So
Phase 2 StartPhase 2 Start: A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other
Phase 2 StartPhase 2 Start: A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitu
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Saf
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of C — BMY Phase 3 Readout | BioSniper